ARS Pharmaceuticals, Inc.

8.98-0.41 (-4.37%)

Oct 29, 4:00:00 PM EDT · NasdaqGM · SPRY · USD

Upcoming Earnings

Report date

Nov 12, 2025 (in 13 days)

Key Stats

Market Cap

887.46M

P/E (TTM)

Basic EPS (TTM)

-0.48

Dividend Yield

Recent Filings

8-K

9/29/25Sep 29, 2025

8-K

8/28/25Aug 28, 2025

10-Q

8/13/25Aug 13, 2025

8-K

8/13/25Aug 13, 2025

8-K

6/26/25Jun 26, 2025

About

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

CEO

Mr. Richard E. Lowenthal M.B.A., M.S., MSMSEL

IPO

12/4/2020

Website

https://ars-pharma.com

Employees

162

Sector

Healthcare

Industry

Biotechnology